somerset pharmaceuticals, inc. , a wholly owned subsidiary of mylan inc. ,
received approval from the fda for emsam® transdermal
selegiline, on february 27 of 2006. Emsam® is the
first transdermal treatment for major depressive disorder. All aspects of the
emsam® product related to its design, chemistry,
manufacturing and controls were the result of the integration of the talents
and expertise of mti scientists. Emsam® is
manufactured by mti.
antidepressants increased the risk of suicidal thinking and behavior
(suicidality) in short-term studies in children and adolescents with major
depressive disorder (mdd) and other psychotic disorders. Anyone considering the
use of emsam® or other antidepressants in a child or
adolescent must balance this risk with the clinical need.
emsam® is not indicated for use in pediatric patients.
for additional details please see full prescribing information, including boxed
Molecular formula:HNO3 Molecular weight:63.01 CAS NO.:7697-37-2 Property:Pure nitric acid is colorless liquid with pungent odor,it's density is ...view details
The E.L.I.T.E. Series, designed for detection and identification of trace explosives and explosives precursors, is field-proven and currently in use ...view details
featuresn-acetyl cysteine (nac) 500 mg capsules contain a highly stable form of cysteine, an important sulfur-containing amino acid. the ...view details
sending enquiry ....